The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Quizartinib granted approval by the EC for patients with newly diagnosed FLT3-ITD-mutated AML
On November 9, 2023, quizartinib, an oral selective type II FLT3 inhibitor, was approved by the European Commission (EC) in combination with standard cytarabine and anthracycline induction, standard cytarabine consolidation chemotherapy, and as a maintenance monotherapy for the treatment of adult patients with newly diagnosed FLT3-ITD-mutated acute myeloid leukemia.1
This approval is based on a recent positive opinion by the European Medicines Agency’s Committee of Medicinal Products for Human Use, previously covered by the AML Hub, and results from the QuANTUM-First trial (NCT02668653).1 Quizartinib has also been approved by the U.S. Food and Drug Administration and in Japan for the same indication.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?
